8-K ·Filed Jul 2, 2026

CRIS

CURIS INC
NEUTRAL
Impact 3/10
Horizonimmediate Processed3mo ago SEC0001108205-26-000078
8-K context-dependent: Items 3.03
Actionable Insight • Neutral

The reverse split is a technical adjustment to maintain Nasdaq listing compliance. Monitor the stock price post-split for ability to sustain above $1.00 bid price. No fundamental change in business outlook; watch for potential future financing or operational updates.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
CRIS ▲ +1331.04% at T+20d
NEUTRAL call ✓ call won +1331.04% · α vs SPY +1331.46% · entry $0.3466 → $4.96
Next anchor: T+1d due 3mo ago
Entry anchored
Jul 1, 03:59 PM ET
via exchange tick
T+1d
—
call — · α —
—
due 3mo ago
T+5d
+1331.04%
call +1331.04% · α +1330.11%
$4.96
settled 3mo ago
T+20d
+1331.04%
call +1331.04% · α +1331.46%
$4.96
settled 2mo ago
T+60d
—
call — · α —
—
due 4d ago

Price Chart

Loading chart...

Executive Summary

Curis Inc. filed a certificate of amendment to effect a 1-for-20 reverse stock split of its common stock, effective July 2, 2026. Trading on a split-adjusted basis begins July 6, 2026, under the same ticker CRIS. The reverse split is a routine capital structure adjustment, likely to maintain Nasdaq listing compliance given the company's $16M market cap.

Key Facts

  • 1-for-20 reverse stock split effective 5:00 p.m. ET on July 2, 2026
  • Trading on split-adjusted basis begins at market open on July 6, 2026
  • Ticker symbol CRIS unchanged; new CUSIP 231269408
  • No fractional shares issued; fractional interests rounded up to nearest whole share
  • Par value remains $0.01 per share; authorized share count unchanged at 567,514,300 shares of common stock
  • Outstanding warrants, RSUs, stock options, and equity incentive plan shares adjusted proportionally

Financial Impact

No direct financial impact; reverse split reduces outstanding share count by 20x but does not change total equity or authorized shares

share countstock price

Risk Factors

  • Stock may fail to maintain minimum bid price post-split, leading to delisting risk
  • Reverse split often signals financial distress; further dilution from equity offerings possible

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001108205-26-000078
Document: crisex31-certificateofamen.htm0001108205-26-000078
Document: 0001108205-26-000078-index-headers.html0001108205-26-000078
Document: 0001108205-26-000078-index.html0001108205-26-000078
Document: 0001108205-26-000078.txt0001108205-26-000078
7 reports for CRIS
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+60▲ +82.45%May 22, 2026
Filters
Rows
Reports for CRIS — sortable, filterable
TypeNow
Aug 13, 2026
7w ago
EFFECT
BEARISH ★ 6/10
$1.87 $1.13▲ +39.57%▲ +37.83%$0.8034 (+57.04%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 6/10
$5.02 $1.49▼ −70.32%▼ −73.31%$0.8034 (−84.00%)
Jul 2, 2026
13w ago
8-K
NEUTRAL ★ 3/10
$0.3466 $4.96▲ +1331.04%▲ +1331.46%$0.8034 (+131.79%)
May 22, 2026
19w ago
8-K
BEARISH ★ 6/10
$9.80 $6.80▲ +30.61%▲ +28.55%$0.8034 (+91.80%)
May 12, 2026
20w ago
8-K
BEARISH ★ 7/10
$10.00 $8.60▲ +14.00%▲ +13.39%$0.8034 (+91.97%)
May 1, 2026
22w ago
8-K
BEARISH ★ 8/10
$11.60 $10.00▲ +13.79%▲ +19.58%$0.8034 (+93.07%)
Mar 23, 2026
27w ago
EFFECT
NEUTRAL ★ 4/10
$0.7400 $0.6000▼ −18.92%▼ −26.34%$0.8034 (+8.57%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (37h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access